Recent Company News

• 08:18 PM ET May 18, 2026
  

  Quoin Pharmaceuticals To Announce Corporate Update and Fourth-Quarter and Full-Year 2025 Financial Results

• 08:33 AM ET May 07, 2026
  

  Quoin Pharmaceuticals reports Q1 EPS ($1.77) vs FactSet ($2.17) [3 est, ($2.53)-(1.72)] ($6.43, 0.00)

• 05:45 PM ET May 04, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:48 AM ET May 04, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:09 AM ET May 04, 2026
  

  Quoin Pharmaceuticals initiated buy at Lucid Capital Markets ($6.21, 0.00)

• 08:32 AM ET Apr 28, 2026
  

  Quoin Pharmaceuticals provides clinical and regulatory update for QRX009 topical rapamycin development programs ($5.46, 0.00)

• 08:32 AM ET Mar 26, 2026
  

  Quoin Pharmaceuticals reports Q4 EPS ($1.74) vs year-ago ($12.39) ($9.27, 0.00)

• 08:35 AM ET Mar 25, 2026
  

  Quoin Pharmaceuticals provides clinical and regulatory update from constructive Type C meeting with FDA for QRX003 in netherton syndrome ($8.00, 0.00)

• 08:31 AM ET Mar 11, 2026
  

  Quoin Pharmaceuticals announces FDA grants fast track designation for QRX003 for treatment of Netherton Syndrome ($8.59, 0.00)

• 08:31 AM ET Jan 27, 2026
  

  Quoin Pharmaceuticals announces submission to Japanese MHLW for orphan drug designation for QRX003 in netherton syndrome ($9.60, 0.00)